Physician profile
Bennett Hong
NPI 1700230372
$3,307.56
in general payments reported to CMS, 2019-2025
20 companies · $568 in 2025
The $568 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.63 · 2021: $23.62 · 2022: $325 · 2023: $539 · 2024: $1,821 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.02 | 2023-2025 | |
| Alcon Vision LLC | $404.62 | 2022-2025 | Clareon, Tryptyr, Simbrinza |
| Harrow Eye, LLC | $322.91 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $240.76 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Miebo |
| Sight Sciences, INC. | $211.19 | 2022-2024 | Omni Surgical System, Tearcare System |
| Rxsight INC | $160.96 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $91.17 | 2022-2025 | |
| Astellas Pharma US INC | $67.00 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $65.24 | 2024-2025 | Xdemvy |
| Amgen INC. | $50.98 | 2024 | Tepezza |
| Glaukos Corporation | $49.36 | 2023 | |
| Oyster Point Pharma, INC. | $44.00 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $42.22 | 2023 | Catalys System |
| Horizon Therapeutics Plc | $37.85 | 2023 | Tepezza |
| Sandoz INC. | $34.97 | 2024 | Cimerli |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $32.43 | 2024 | Oxervate |
| Carl Zeiss Meditec Cataract Technology INC. | $31.63 | 2020 | |
| Genentech USA, INC. | $24.70 | 2024 | Vabysmo |
| Kala Pharmaceuticals, INC. | $23.62 | 2021 | |
| Coopervision INC. | $16.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennett Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.